Study to Assess SLN124 in Patients With Polycythemia Vera

Study Number

4545025

Phase

I/II

Age Group

Adult

Principal Investigator

Steven Green

Purpose

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Check your eligibility for this trial

Check now

Full Title

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

ClinicalTrials.Gov ID

NCT05499013

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.